Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop

S Robert Levine; Martin G Myers; Ryan Barunas; Dolly S Chang; Sanjoy Dutta; Ted Maddess; Jeffrey M Liebmann; Steve Sherman; Melvina Eydelman; Jennifer K Sun; Wiley Chambers; Kerstin Wickström; Ulrich F O Luhmann; Martin Pallinat; Adam Glassman; Lloyd Paul Aiello; Dorene S Markel; Thomas W Gardner

doi:10.1167/tvst.12.11.33

Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop

Transl Vis Sci Technol. 2023 Nov 1;12(11):33. doi: 10.1167/tvst.12.11.33.

Authors

S Robert Levine¹, Martin G Myers², Ryan Barunas³, Dolly S Chang⁴, Sanjoy Dutta⁵, Ted Maddess⁶, Jeffrey M Liebmann⁷, Steve Sherman⁸, Melvina Eydelman⁹, Jennifer K Sun¹⁰, Wiley Chambers¹¹, Kerstin Wickström¹², Ulrich F O Luhmann¹³, Martin Pallinat¹⁴, Adam Glassman¹⁵, Lloyd Paul Aiello¹⁰, Dorene S Markel¹⁶, Thomas W Gardner^{1

17}

Affiliations

¹ Mary Tyler Moore Vision Initiative, Greenwich, CT, USA.
² University of Michigan Caswell Diabetes Institute, Ann Arbor, MI, USA.
³ JDRF Northeast Ohio & Michigan Chapter, Southfield, MI, USA.
⁴ Genentech, South San Francisco, CA, USA.
⁵ JDRF, New York, NY, USA.
⁶ John Curtin School of Medical Research, Australian National University, Canberra, Australia.
⁷ Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.
⁸ Regeneron Pharmaceuticals, Tarrytown, NY, USA.
⁹ Food and Drug Administration, Rockville, MD, USA.
¹⁰ Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
¹¹ Food and Drug Administration, Silver Spring, MD, USA.
¹² Icelandic Medicines Agency, Reykjavik, Iceland.
¹³ Roche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center, Basel, Switzerland.
¹⁴ Visiontree Software, Inc., San Diego, CA, USA.
¹⁵ Jaeb Center for Health Research, Tampa, FL, USA.
¹⁶ Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, USA.
¹⁷ Department of Ophthalmology & Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.

Abstract

The Mary Tyler Moore Vision Initiative Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop was held on October 22, 2022 to accelerate progress toward establishment of useful clinical and research endpoints and development of new therapeutics that have important relevance across the full spectrum of DRD pathology. More than 90 patient representatives, clinicians, scientists, funding and regulatory agencies, diagnostic, therapeutic and biotech industry representatives discussed the needs for new diagnostic and therapeutic approaches to prevent and restore retinal neurovascular unit integrity. Phase I of the MTM Vision Initiative plans, notably updating the DRD staging system and severity scale, establishing a human ocular biorepository and resource, and clinical endpoints and biomarker development and validation, was emphasized.

MeSH terms

Diabetes Mellitus*
Diabetic Retinopathy* / diagnosis
Diabetic Retinopathy* / therapy
Humans
Retina